Ignite Creation Date:
2024-10-26 @ 3:41 PM
Last Modification Date:
2024-10-26 @ 3:41 PM
Study NCT ID:
NCT06612671
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
None
First Post:
2023-09-09
Brief Title:
Treatment Outcomes of Retroperitoneal Sarcoma
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Prognostic Factors and Oncological Outcome Analysis of Retroperitoneal Sarcoma
Status:
ACTIVE_NOT_RECRUITING
Status Verified Date:
2024-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Investigators tried condult a retrospective study to analysis the prognostic factors and oncological outcome analysis of Retroperitoneal Sarcoma treated in our high volume medical center
Detailed Description:
Retroperitoneal Sarcoma RPS which is a rare disease which incidence is 179100000 The treatment is difficult to due to it anatomy position which often invade to multiple organs and cause the complete surgical resection to be very complex and difficult It was known to sacrifice one side kidney will improve the resection rate To this days successful surgical resection was still the gold standard that provide most benefit in overall survival To reach that goal pre-operative radiotherapy was applied to RPS which intended to achieve similar effect in rectal cancer for the down staging effect and improved the respectability but with limited benefit Herein investigators conducted this study to find the best way to achieve successful surgical resection and prognostic factor analysis
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None